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Abstract: Non-LTR retrotransposons are the only known class of active mobile genetic 
elements in the human genome. These elements are endogenous mutagens that can contribute to 
disease pathologies through a variety of mechanisms.  One of the least documented mechanisms, 
by which active retrotransposons can contribute to disease, is through the creation of new CpG 
island (CGIs)s at their insertion sites. In fact, more than half of all CGIs in the human genome 
are thought to be derived from retrotransposons. There is evidence that suggests that repetitive 
DNA elements played a critical role in the establishment of genome-wide methylation patterns 
and that DNA methylation of CpGs evolved primarily as a host defense mechanism against 
transposable elements.  Despite this fact, not much is known about the epigenetic impact that 
retrotransposons can have on their insertion sites. To gain a better understanding of this impact, 
we looked at the effect that non-LTR retrotransposons have on the methylation status of flanking 
DNA in three different systems. The first system involved an L1 insertion into the 5' UTR of the 
androgen receptor gene of a patient that caused Partial Androgen Insensitivity Syndrome. The 
second system involved an antisense SVA insertion into intron 32 of the TATA-binding protein-
associated factor-1 (TAF1) gene that caused X-linked dystonia parkinsonism. The third system 
involved full-length L1 insertions introduced into a human ovarian teratocarcinoma cell-line. In 
all 3 systems, we hypothesized that the presence of the new non-LTR retrotransposon insertion 
would alter the methylation status of the flanking DNA CpG sites both upstream and 
downstream of the insertion sites. We have obtained preliminary data that has laid the 
groundwork for the successful completion of this research at a later date following the reopening 
of the university.  
Primary Readers and Advisor: Dr. John Goodier, Dr. Haig Kazazian, Jr. 
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Chapter 1: A review: the role of retrotransposon insertion in disease  
It has been roughly seventy years since Barbara McClintock first discovered the existence 
of transposable elements (TEs)in maize [1]. Since then, there has been a lot of research and tools 
developed to better understand the biological significance of mobile DNA in the genome. 
Formerly considered “junk DNA,” it is now understood that these elements have played a huge 
role in genome evolution and that they can contribute to disease [11-13]. This review will focus 
on a portion of what is currently understood about the biology of transposons and their role in 
human disease.   
TEs, also known as “jumping genes”, are DNA sequences that can mobilize from one 
genomic location to the next. The ability of TEs to “jump” is mediated by key endogenous 
proteins such as DNA transposase and reverse transcriptase. TEs that mobilize using gene-
encoded proteins are known as autonomous elements. TEs that rely on autonomous element 
proteins to mediate their mobilization in trans are known as non-autonomous elements. 
Altogether, these transposons constitute approximately half of the mammalian genome. At least 
two-thirds of the human genome is thought to be repetitive or repeat-derived [2,7,8].  
TEs are divided into two groups based on their mechanisms of genomic insertion. The 
first group are the DNA transposons; these mobilize via a DNA intermediate. The second group 
are the retrotransposons; these mobilize via an RNA intermediate. See Figure 1. 
I. DNA transposons 
DNA transposons have relatively low copy numbers and occupy only 3% of the human 
genome [3]. These elements are inactive in all primates; the only known exception was found to 
be a family of piggyBac elements in bats [4]. There are several families of DNA transposons 
present within mammalian genomes. These families are classified based on their transposase and 
the biochemical mechanism of transposition that they employ [5]. Generally, all DNA 
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transposons mobilize via a “cut and paste” mechanism. This process involves the self-excision of 
the DNA element from its current site, followed by its integration at a new target site. There are a 
couple of essential steps, in the biochemistry of this process that all known families of DNA 
transposons share [14,15]. At the donor site, the exposure of 3’ hydroxyl groups at the 
transposon’s ends always occurs. At the target site, a strand transfer reaction, driven by a 
nucleophilic attack of the exposed 3’ hydroxyl group also always occurs. This results in the 
integration of the element at its target site [5]. The target site tends to be close to the original 






                                            
 
       
Figure 1.1: Mechanisms of Transposition [31]. 
 
II. Retrotransposons 
These elements mobilize within the genome via a “copy and paste” mechanism (Fig. 1). 
The process involves the transcription of the retrotransposon into RNA, the reverse transcription 
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of the RNA into cDNA and the integration of the cDNA copy into a new genomic site [6]. 
Historically, retrotransposons are subdivided into two groups based on whether they possess 
long-terminal repeats (LTR) or not (non-LTR). 
LTR retrotransposons 
LTR elements have been found in the genomes of many eukaryotic organisms (e.g. Ty1 
in yeast) [19,20]. They make up ~8% of the human genome and are believed to be mostly 
inactive; HERV-K may be the exception [6].  LTR elements are very similar to retroviruses, 
which suggests they share a common evolutionary history [21]. Both have been found to possess 
the gag and pol genes, which encode the proteins necessary for their replication. The main 
structural difference is that LTR elements, unlike retroviruses, lack a fully functional env gene. 
This means that they can only mobilize within their genome of origin [18].  In humans, LTR 
elements are found to exist in truncated and mutated forms or as solo LTRs [5]. This is the 
reason why LTR elements are generally considered to be inactive in humans, although the 
existence of active elements has not been ruled out [45,46]. 
There are some common components in the life cycle of a typical LTR retrotransposon. 
The cycle begins with the transcription of the element by RNA Polymerase II at an internal 
promoter in the 5’ LTR region. The RNA is then subsequently transported to the cytoplasm 
where it is translated. The resulting proteins form a virus-like-particle (VLP) containing the 
RNA. The reverse transcriptase protein then reverse transcribes the retrotransposon RNA into a 
cDNA copy. This complete cDNA is transferred back into the nucleus where integration takes 
place [21]. See Figure 2.  
Non-LTR retrotransposons 
Non-LTR retrotransposons are the only class of TEs that are still active in the human 
genome [13, 23]. The long interspersed element-1 (LINE-1 or L1) is the only autonomous active 
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non-LTR element. The other non-LTR elements (e.g. short interspersed element (SINE) Alus 
and SVAs) are non-autonomous; they cannot mobilize without L1 proteins. 
L1s 
As the only autonomous non-LTR elements, L1s occupy approximately 17% of the 
human genome. Most L1s are inactive due to mutations, rearrangements and truncation events. 
However, on average, every human has roughly 80-100 L1 elements that are still active [23]. An 
active L1 is ~6 kb in length and has a ~900 bp 5’ untranslated region (UTR), a ~200 bp 3’ UTR, 
2 open reading frames (ORF1 and ORF2) on the sense strand, and a 3' UTR. The 5’ UTR of an 
L1 acts as an internal promoter. The L1 3’ UTR has a polyA tail and a weak polyA signal 
(AATAAA) which is responsible for transcription termination [6, 23]. ORF1 encodes a ~40 kDa 
RNA-binding protein with chaperone activity, that binds RNA molecules as a trimer [47]. ORF2 
encodes a ~150 kDA protein with endonuclease (EN) and reverse transcriptase (RT) activities. 
Both proteins, ORF1p and ORF2p, are essential for L1 retrotransposition. L1s also have an 
antisense promoter in the 5’ UTR that encodes a short ORF0p product of unknown function [24]. 
The L1 retrotransposition cycle begins in the nucleus with the transcription of a 
bicistronic mRNA. There are several transcription factors involved in this process. Following 
transcription, L1 mRNA is translated in the cytoplasm to produce ORF1p and ORF2p [25]. 
These proteins assemble with L1 RNAs to form a ribonucleoprotein particle (RNP). Some of 
these RNPs then re-enter the nucleus, where an integration mechanism termed target-primed 
reverse-transcription (TPRT) takes place [26]. The genomic site of integration is largely 
determined by the endonuclease (EN) activity of ORF2p. This enzyme recognizes a consensus 
sequence, of the form 5’-TTTT/AA-3’ and cleaves the bottom strand of the target site to free up 
a 3’ hydroxyl [23]. The L1 RNA polyA tail anneals to the single overhang produced and ORF2p 
uses the free 3’ hydroxyl as a primer for reverse transcription. This generates the first strand of 
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L1 cDNA. Second-strand cleavage and synthesis occur soon afterwards, and the structure is 
resolved and integrated into the genome by cellular mechanisms that have not been clearly 
defined. Upon TPRT completion, the retrotransposon insertion is characterized by target site 
duplications (TSD), a hallmark of this process. Occasionally during TPRT, a process called 















Figure 1.2: The Mechanisms of Retrotransposon Integration [64] 
Alus  
Alus constitute ~10% of the human genome. This noncoding short-interspersed element 
(SINE) is ~300 bp long. It is also the most abundant retroelement in the human genome with 
every human possessing over 1 million copies on average [32]. Structurally, Alus are dimeric 
with left and right monomers connected by an A-rich linker. The left monomer contains an 
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internal RNA polymerase III promoter, with A and B boxes, for transcription [23]. Alus are 
dependent on L1 proteins for mobilization. Cell retrotransposition assays have shown that Alus 
require L1 ORF2p to mobilize in trans [28]. While L1 ORF1p has been found to not be essential, 
it does, however, enhance Alu retrotransposition [33]. Alus, like L1s, upon insertion are 
characterized by poly A tails of varying length and TSDs. Both of these are hallmarks of TEs 
that undergo the TPRT process. See Figure 2.  
SVAs 
The other non-autonomous non-LTR retroelement in humans is the SINE-VNTR-ALU 
(SVA). This hominid-specific element comprises approximately 2% of the human genome, and 
is the youngest active retrotransposon [6]. The structure of an SVA, 5’ to 3’, consists of:  a) 
hexameric repeats (CCCTCT)n, b) an antisense Alu-like domain, c) a GC-rich variable number 
of tandem repeats (VNTR) domain, and d) a SINE-R domain derived from an extinct HERV-K 
[28]. Only L1 ORF2p is required for SVA retrotransposition. However, L1 ORF1p has, in 
retrotransposition assays, been found to enhance SVA insertions [29,48]. SVA genomic 
insertions also contain hallmarks of L1-mediated retrotransposition, including both the presence 






















Figure 1.3: The Different Types of Transposable Elements in Mammals. [Adapted from (30,31)]. 
Abbreviations: Mariner: DR, direct repeat; ITR, inverted terminal repeat; HERV: LTR, long terminal repeat; Gag, 
group-specific antigen; Pol, polymerase; Env, envelope; LINE-1: RT, reverse transcriptase domain; EN, 
endonuclease domain; TSD, target site duplication; Alu: L, Left monomer; R, Right monomer; SVA: VNTR, variable 
number tandem repeats, SINE-R, short interspersed element of HERV origin. 
 
III.  The role of Retrotransposons in human disease 
In 1988, Dr. Haig Kazazian and colleagues provided the first piece of evidence that 
human disease could be caused by de novo retrotransposon insertions [34]. In one patient case, 
they found a truncated L1 insertion in a boy with hemophilia A. The insertion was present within 
exon 14 of the factor VIII gene; a gene located on Chromosome X. This same insertion was not 
found in the parents’ genome who were normal. However, the mother did have what was 
determined to be the progenitor full-length insertion present on her chromosome 22 [30,34]. This 
evidence suggested that L1 insertion events could occur spontaneously in the gametes or during 
early embryogenesis. It suggested that L1s are still active in the human genome today and that 
they could cause disease. Now we know that every human has roughly 80-100 potentially active 
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L1 elements in their genome [23].  Moreover, any two humans differ on average by ~300 L1 
insertions [11].  
There are now >130 documented cases of retrotransposition events associated with 
human disease [30]. These cases include both de novo and inherited occurrences, and germline 
and somatic insertion events. Each documented case has contributed to our understanding of 
retrotransposon biology and the mechanisms by which insertions can cause/contribute to disease. 
Mechanisms by which Insertions can cause/contribute to disease 
   There are a variety of mechanisms by which retrotransposons can cause or contribute to 
disease [11]. The mechanism observed most often is insertional mutagenesis. This occurs when a 
retrotransposon inserts into a gene or regulatory region and directly disrupts its normal 
functioning. This leads to readily observable phenotypes. Historically, this mechanism is 
exemplified by the first reported case of a disease-causing insertion in the germline (the 
hemophilia A case) [34]. An additional historical example of insertional mutagenesis would be 
the first documented instance of a somatic insertion causing disease [35]. This case involved L1 
insertion into the last exon of the APC gene, a tumor suppressor gene, causing a sporadic case of 
colorectal cancer.  
 In addition to disrupting genomic sequences upon insertion, retrotransposons can 
contribute to genomic instability by causing deletions and by transducing flanking genomic 
sequences upon insertion [49-51]. Transduction events occur in both SVAs and L1s to varying 
degrees. In 3’ transduction, the RNA transcription machinery bypasses the weak polyA signal 
present in its 3’UTR and uses an alternative polyA signal downstream in the 3’ flanking 
sequence. This means L1s have the potential to mediate exon shuffling (if they mobilize an 
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exon/regulatory sequence with them as they insert) [37]. In 5’ transduction, a promoter upstream 
of the retrotransposon sequence transcribes through the retrotransposon. 
 Alus and L1s insertions can also contribute to disease through ectopic recombination 
(ER). ER events can lead to several types of genomic rearrangements (e.g. deletions, duplication, 
translocations, etc.). For example, a nonallelic homologous recombination event, between two 
antisense Alu elements, caused a ~5 kb deletion in a region of the Low-density lipoprotein 
receptor gene of a patient, which resulted in hypercholesterolemia [39].  
There are many mechanisms in which a TE can contribute to genomic instability and 
cause disease. Therefore, it makes sense that host organisms have multiple defense mechanisms 
to prevent their spread.  
Natural Defense Mechanisms against Retrotransposon Insertions 
 Organisms have developed several defense mechanisms to prevent retrotransposons from 
generating genomic instability and consequently disease. These mechanisms are enacted at 
various stages of development and have been found to involve many restriction factors (e.g. 
APOBECs, MOV10, etc.) [6]. A main mechanism of retrotransposon restriction is gene 
silencing. Gene silencing occurs within primordial germ cells (PGCs). DNA methyltransferases 
and associated proteins (e.g. Dnmt3L, DNMT3A) act in concert to methylate the 5’ UTR of 
retrotransposons, which significantly suppresses TE action. Within the germline, retrotransposon 
activity is regulated at several levels by the small interfering RNA PIWI/piRNA pathway [6,23]. 
At the chromatin level, the PIWI/piRNA pathway promotes genome-wide DNA and histone 
methylation of TEs, which greatly suppresses their activity. At the post-transcriptional level, 
PIWI/piRNA complex can cleave TE transcripts via RNA interference. There are several other 
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natural defense mechanisms that organisms employ to restrict RI events. There is a constant 
battle between TEs and their host organisms. 
IV. Area of study: DNA Methylation and non-LTR retrotransposons 
We hypothesized that de novo non-LTR retrotransposon insertions could affect the 
methylation status of flanking DNA. There is evidence to support this thinking.  Both L1s and 
SVAs are known to possess CpG islands (CGIs) near their 5' termini [52]. See Figure 1,4. Of the 
28 million CpG dinucleotides present in the human genome, 27% and 12% are contained in 
SINES and LINEs, respectively [53].  SVAs are ~ 60% GC-rich, exceeding 70% GC content 
within their VNTR region [54]. Additionally, more than 60% of human SVAs are present in or 
within 10 kb of genes [55]. Thus, each new full-length SVA or L1 insertion introduces novel 









Fig. 1.4.  CpG islands predicted in L1 and SVA by the CPGplot algorithm.  The SVA CpG island (CGI) is 
present within its Alu-like region. The L1 CGI is present in its 5’ UTR region. 
 
There is evidence, especially from plants, that suggests that repetitive elements play a critical 
role in the establishment of genome-wide methylation patterns.  For example, methylation 
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spreading in cis from plant retrotransposons into flanking DNA regions has been found [58, 59].  
The occurrence of this phenomenon, in mammals, has not been studied as extensively. However, 
it was found that mouse B1 SINEs can act as "methylation centers" [60]. Additionally, 
methylation spreading from human Alus into flanking DNA has been implicated in the silencing 
of some tumor suppressor genes [61]. There is also evidence that SVAs can affect the 
methylation status of CpGs present in flanking DNA regions. In one study, a 60% loss of 
methylation in DNA upstream of a human polymorphic SVA element was observed [62]. There 
have also been cases where L1s insertions have been observed to affect the methylation status of 
flanking CpG residues [63].  
To test the hypothesis that new non-LTR retrotransposon insertions can affect the 
methylation status of neighboring DNA, we used whole genome bisulfite conversion, site-
specific PCR, TOPO-TA cloning, and Sanger sequencing to examine methylation effects in three 
different systems involving unique full-length non-LTR retrotransposon insertions: 
1) an L1 insertion into the 5' UTR of the androgen receptor gene of a patient that caused 
Partial Androgen Insensitivity Syndrome (Batista et al 2019). See Chapter 2.  
2) an SVA insertion in antisense orientation into intron 32 of the TATA-binding protein-
associated factor-1 (TAF1) gene that caused X-linked dystonia parkinsonism, a rare 
movement disorder that almost exclusively afflicts males of Filipino descent (Makino et 
al. 2007). TAF1 gene encodes the largest subunit of the TFIID transcription complex. See 
Chapter 3: future study #1.  
3) 5 clonally derived human ovarian teratocarcinoma PA1 cell lines, each containing a full-
length L1 introduced into their genomes by a cell culture retrotransposition protocol. See 
Chapter 3: future study #2. 
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Chapter 2: Methylation Analysis of DNA flanking L1 in PAIS case 
Introduction 
Androgen Insensitivity Syndrome (AIS) is the most common cause of Disorders of Sexual 
Development (DSD) in individuals with a 46, XY karyotype. It is usually caused by mutations in 
the androgen receptor (AR) gene. This gene, located at Xq11-12, has 8 exons that encode the 
androgen receptor [41]. It is responsible for regulating the expression of genes involved in sexual 
development and differentiation. In AIS, AR mutations result in varying degrees of 
undervirilization of the external genitalia. AIS clinically presents itself in 3 forms: complete 
(CAIS), partial (PAIS) and mild (MAIS). In CAIS, a 46, XY individual has completely female 
external genitalia. In MAIS, a 46, XY individual has completely male external genitalia 
associated with infertility and possible gynecomastia [41]. The PAIS clinical phenotype is a large 
spectrum, of undervirilization, between the two extremes of CAIS and MAIS. Out of all 3 forms 
of AIS, PAIS has been found to be the most difficult to diagnose [43]. Yet, it is also the most 
common form of AIS with an estimated incidence rate of 1 in 130,000 births [40]. One reason 
why PAIS is difficult to diagnose is because causative AR gene mutations, in coding regions and 
splice sites, have only been identified in <25% of patients who have a clinical diagnosis of PAIS. 
This greatly contrasts with CAIS, in which the mutation has been identified within the gene in 
>90% of cases [41]. This suggests that factors outside of the AR gene, which influence its’ 
expression, may contribute to PAIS. In the literature, this has been referred to as AIS type II 
[42]. By looking at mutation-negative cases of AIS, we can gain a better insight into its 
etiologies.   
Long-interspersed elements (L1s) belong to a class of DNA elements in the human genome 
called transposable elements (TE). TEs are mobile elements that can insert into new locations in 
the genome. L1s are the only active autonomous retroelement and is responsible for mobilizing 
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other elements such as SVAs and Alus. Retrotransposon insertion (RI) has been found to cause 
or contribute to several somatic and germline diseases. One of the main mechanisms, by which 
retrotransposons can cause disease is insertional mutagenesis. Insertional mutagenesis typically 
involves the disruption of a gene via insertion into a coding region, a splice site or some other 
regulatory region [6]. This is the predominant mechanism observed in disease-causing RI cases. 
Another potential mechanism, by which active RIs can cause disease, is by causing epigenetic 
changes at the integration site. There is supporting evidence for this mechanism. For example, in 
teratocarcinoma cell lines, alterations in local histone modifications have been observed 
following L1 insertion suggesting that L1s could potentially epigenetically impact a target site 
[43]. By exploring cases in which RI may affect the epigenetic profile of an insertion site, we 
gain more knowledge about the biological properties of retrotransposons and the mechanisms by 
which they could cause disease.   
A former researcher in our lab, Dr. Rafael Batista, discovered a case of PAIS where whole 
exon sequencing of the AR gene showed no mutation. This fact seemingly conflicted with the 
observation that AR gene expression, in this patient, was significantly impaired [41]. Upon 
further analysis, a L1 insertion was found in the 5’ UTR of the patient’s AR gene. Familial 
analyses revealed that the mother was a carrier for the insertion, however, was unaffected 
(Table2.1). We hypothesized that the significant reduction in AR gene expression observed in 
this patient was likely due to the epigenetic effect the L1 insertion has on the flanking DNA at 
the insertion site.  We expected to see a significant difference in the methylation status of CpGs 
flanking the 5’ UTR of the PAIS patient's full-length L1 insertion than seen at the same CpGs in 
a comparable control lacking the insertion (the patient's normal XY brother). 
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Material and Methods: 
AIS Genetic Analysis Studies: We obtained genomic DNA from the PAIS patient from 
Rafael Batista at the University of São Paulo. The DNA was originally obtained from peripheral 
blood leukocytes using the proteinase K-SDS salting-out method. The entirety of the Androgen 
Receptor (AR) gene was sequenced using primers designed via the Primer3 bioinformatics 
program [75]. The PCR products were prepped following the ABI Prism BigDye Terminator 
Cycle Sequencing Ready Reaction Kit protocol (Life Technologies Corp., Carlsbad, CA). The 
products were analyzed using the ABI Prism Genetic Analyzer 3130XL 
(LifeTechnologiesCorp.). 
Bisulfite Primer Design: Several bisulfite primers were designed with the aid of MethPrimer 
bioinformatics tool and Primer3Plus [75,76]. These primers were between 20-30 bp in length and 
were designed to preferably amplify regions between 200-500 bp. The first set of primers were 
designed so that the 5’ AR flank and L1 would be amplified. A second set of primers were 
designed so that the 3’ AR flank and the 3’ end of the L1 would be amplified. A third set of 
primers were designed to amplify the empty site AR DNA for cases without the L1 insertion, 
including the promoter core region. (Fig 2.2).  All these primers were designed such that they 
would amplify their respective regions with at least 3 CpG sites present within an amplicon. Due 
to limited amounts of patient DNA, we first tested the third set of primers in RPE-1 DNA. The 
RPE-1 DNA modeled the no insertion case.  We amplified the “empty site” in the RPE-1 DNA. 
We also amplified the region just downstream of where the L1 insertion would be if the RPE 
cells had the insertion. This region is where the AR gene promoter core in the 5’UTR is located. 
 Bisulfite DNA sequence analysis: Bisulfite conversions of the DNAs were performed using the 
EpiTect Fast bisulfite kit (Qiagen) according to the manufacturer’s instructions. To determine the 
DNA methylation status, this treatment converts unmethylated cytosine resides to thymine, while 
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those that are methylated (5-methylcytosines) are resistant to treatment and stay as cytosines. 
Normally, mostly all non-CpG cytosines are not methylated in the human genome. This allows 
the calculation of the conversion efficiency of the bisulfite process. We calculate the conversion 
efficiency by obtaining the ratio of converted to non-converted non-CpG Cs in each sample. A 
DNA sample with all non-CpG cytosines sites converted to thymines are considered to have a 
conversion efficiency of 100%. 
Bisulfite-Nested PCR:  
Bisulfite-treated DNAs were amplified by a nested PCR protocol. Reagents from the 
Epitect MSP kit (QIAGEN) were used. PCR was performed in a volume of 10 μl containing:  2x 
EpiTect Master Mix, 5 μM of each primer and 10 ng of BS-treated DNA. Products of expected 
size were run on a 1% agarose gel.  
1st BS PCR conditions:  
1) 95 °C for 10 min 
2)  94 °C– 15 sec  
3) 50-58 °C – 30 sec 
4)  72°C – 2 min 
5)  72°C– 10 min  
Used 1st PCR product as a template for second PCR.   
2nd BS PCR conditions: 
1) 95 °C for 10 min 
2)  94 °C– 15 sec  
3) 55 °C –30 sec 
4)  72°C –2 min 
5)  72°C– 10 min  
 
 x 30 
 
 




DNA Purification & Sequencing:  PCR products of the expected size were extracted and 
purified following the QIAquick gel extraction kit (Qiagen) protocols. Purified DNAs were 
cloned into a vector following the TOPO TA Cloning kit protocol (pCR2.1, Invitrogen) and then 
transformed into NEB 5-alpha competent cells on agar plates containing 40 ul of X-gal. These 
plates were kept overnight at 37°C. After ~24 hours in the incubator, white colonies were picked 
in order to perform colony PCR.  
Colony PCR Parameters: 
1) 95 °C – 2:30 min 
2) 95 °C – 30 sec  
3) 58°C – 30 sec 
4) 72°C – 1 min 
5) 72°C – 3 min  
The Qiagen Miniprep Kit protocol was followed in order to extract and purify the DNA 











Figure 2.1: AIS Family Pedigree. Arrow points to the PAIS patient (with the L1 insertion) [41]. 
  




Primer Set Name Primer Name 5' to 3' Product size (bp) Total CpGs 
5' AR UTR (out-F) ATTTTAGTGGATATTGAATTTGGAAG 290
5' AR UTR (out-R) CCCTTCTCTTACTCAAAAAAATTCAAC
5' AR UTR (in-F) TTAGTGGATATTGAATTTGGAAGG 286 8
5' AR UTR (in-R) CCCTTCTCTTACTCAAAAAAATTCA
5' AR. Promoter (out-F) GTTGAATTTTTTTGAGTAAGAGAAGGG 410
5' AR Promoter (out-R) CCTCATCCAAAACCAAATAACC
5' AR Promoter. (in-F) TGAATTTTTTTGAGTAAGAGAAGGG 370 14
5' AR Pro. (in-R) GTGAGGATGGTTTTTTTTAAGTTTA
 5' AR UTR L1 insert. (out-F) GGGAGTTAGTTTGTTGGGAGAG 275
5' AR UTR L1 insert. (out-R) CAATCCTACCAAACACTTTCCTTAC
 5' AR UTR L1 insert. (in-F) GGAGTAAGTTTAGAGGTAGAGGAG 239 18






5' AR UTR 









Figure 2.2: PAIS primer set schematic. The first set of primers were designed to amplify the 5’ AR gene 
flank and the 5’ L1 end (green arrows). The second set of primers were designed to amplify the 3‘AR flank 
and the 3’ end of the L1 (blue arrows). The third primer set was designed to amplify regions in the 5’ UTR 
in cases with no insertion; the empty site + promoter core (purple arrows). 




To test whether the presence of the L1 insertion affected the methylation status of flanking 
DNA in the 5’ UTR of the AR gene, we planned to perform site-specific bisulfite PCR in the 
PAIS patient and his normal XY brother. We designed 3 primers sets. The first primer set was 
designed to amplify the 5’ end of the L1 and the 5’ flanking DNA in the PAIS patient. The 
secondary primer set was designed to amplify the 3’ end of the L1 and the 3’ flanking DNA in 
the PAIS patient. The third set of primers was designed to amplify the empty site of the 5’ UTR 
in cases with no insertion (e.g. normal XY brother). We planned to compare the methylation 
status of CpGs in the flanking DNA for the case with the L1 insertion (PAIS) to the case without 
the insertion (normal XY brother). We wanted to see if there were any significant differences in 
the methylation levels of the CpGs in DNA flanking the insertion.  
Due to limited amounts of patient DNA available for testing, we first performed preliminary 
experiments in genomic DNA extracted from RPE-1 cells (Retinal epithelial cells immortalized 
with hTERT). The RPE-1 DNA did not have an L1 insertion present in the AR gene, so it served 
as a model for the no insertion case. In the RPE-1 DNA, we successfully amplified the empty 
site and assessed the methylation status of the CpG sites (Fig. 2.3). The overall conversion 
efficiency was found to be ~99.3%. We also amplified the AR gene core promoter region present 
in the 5’ UTR in the RPE cells (Fig 2.4). We assessed the methylation status of the CpG sites 
present in this region. The overall conversion efficiency was found to be ~99.7%.  
We were able to amplify a DNA region upstream of the L1 insertion in the 5’ UTR of the 
PAIS patient. We assessed the methylation status of the CpG sites (Fig 2.5). The overall 




Figure 2.3: RPE, No insertion schematic- empty site. A) The “empty site,” the region flanking where the L1 
insertion would be present in the PAIS case, was amplified in the RPE DNA. The overall conversion efficiency 

































































































































Figure 2.4: RPE, No insertion case- core promoter region. A) The “promoter” region was amplified in the RPE 
DNA. This region is adjacent to where the L1 insertion would be in the PAIS case. The overall conversion 






Figure 2.5: AR 5’ UTR - L1 insertion case. 
A) In the PAIS patient, a region of their 5’ UTR was amplified. This region was upstream of where the L1 insertion was present. This region 
encompassed 18 CpG sites. The primer which denotes this site is highlighted in yellow).  
 
Key: lowercase is the flanking genomic DNA, uppercase is the L1 sequence, highlighted in gray are the target site duplications (TSDs), in red 
are the CG sites, promoter core region in black.  
 
B) The methylation status of the CpGs were assessed. Generally, CpGs closer to the insertion site were more frequently methylated. 
 
AR 5' UTR L1 insertion




























































































One of the main challenges of bisulfite treatment of DNA is that it is an inherently harsh 
process. Treatment of DNA with bisulfite (HSO3
-) results in the deamination of unmethylated 
cytosines (C) to uracil (U). However, during this process fragmentation of the DNA into small 
single stranded sequences, usually less than 500 nucleotides (nt) long, occurs [78]. For this study, 
we used the Epitect Fast Bisulfite Kit for the conversion process and the Epitect MSP kit for the 
site-specific bisulfite PCR. A study comparing the effectiveness of the various bisulfite 
conversion kits found that the EpiTect Kit recovers ~10.2% of the input DNA with average 
recovery fragment lengths of ~414 nucleotides [80]. Therefore, in order to maximize the 
probability of successfully amplifying a region of interest, the Epitect MSP kit recommends a 
high input concentration of DNA and amplicon sizes of up to ~250 bp. However, due to limited 
amounts of the patient DNA, we were forced to work with lower DNA concentrations. 
Additionally, the lengths of the amplicons that we were interested in generating were typically 
larger than 250 bp. Although more challenging, amplifying larger amplicons using lower 
concentrations of DNA is possible. Both the amplicon length and starting DNA concentration 
were factors that contributed to the difficulty we experienced in completing this project. This 
reality is the main reason why we first decided to model the no-insertion case, normal XY 
brother, in RPE-1 gDNA. By modeling this case in the RPE-1 DNA, we were able to 
successfully obtain a list of several primers that would have likely been able to amplify the 
regions we were interested in amplifying in the normal XY brother.  
In this experiment we gained preliminary data on the methylation status of the CpGs 
upstream of the L1 insertion in the actual PAIS case.  We also modeled what the no insertion 
case might look like in the XY normal brother by using RPE-1 gDNA.  Initially, we 
hypothesized that the significant reduction in AR gene expression observed in the AR patient 
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was likely due to the epigenetic effect the L1 insertion has on the flanking DNA at the insertion 
site.  Therefore, the results that we would expect to see would be a significant increase in 
methylation of CpGs present in DNA flanking the insertion in the PAIS patient as compared to 
the methylation of those same CpG sites in the normal XY brother.  However, we were unable to 
obtain the data necessary for computing meaningful statistical analysis. When we were about to 
amplify the regions of interest in the actual normal XY brother, and obtain sequencing data, the 
emergence of COVID-19 halted our progress.  Johns Hopkins mandated, due to the coronavirus 
pandemic, that all non-essential lab work be stopped, including access to sequencing facilities 
and reagents.   
The successful completion of this project would have required methylation data from 
flanking CpG sites both upstream and downstream of where the L1 insertion is in both the 
normal XY male and PAIS patient. This data must include information about the methylation 
status of the same flanking CpG sites in the case with the insertion (PAIS patient) and the case 
without it (normal XY male). With the entirety of this data we would have been able to perform 
bisulfite conversion methylation analysis by using the Quantification tool for Methylation 
Analysis (QUMA). QUMA is a commonly used program that uses Fisher's Exact Test statistics 
to determine whether any differences in methylation levels are statistically significant [79]. 
QUMA would have allowed us to determine whether the presence of the L1 insertion (in the 
PAIS patient) led to statistically significant changes in the average methylation levels observed 
in each flanking CpG site (both upstream and downstream from the insertion).  
In terms of results, we were expecting the average methylation levels of the flanking CpG 
sites to be significantly elevated in the presence of the L1 insertion (PAIS patient) relative to the 
absence of it (normal XY individual). We expected for this to be the case for CpG sites located 
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both upstream and downstream of the insertion. This result would have supported our hypothesis 
that the L1 insertion elevated the methylation level of the flanking DNA in the PAIS patient. 
This result would have also served as a possible explanation for why the PAIS patient had a 
significantly reduced AR gene expression profile without a mutation in a gene-coding/intronic 
region of their AR gene. This result would have also served as further evidence that an L1 can 
epigenetically affect its site of insertion and in some cases, contribute to disease phenotypes.  
Another potential case study is the mother of the PAIS patient. The mother is a carrier for the 
L1 insertion in one of her X-chromosomes. This means that we could have theoretically looked 
at the methylation status of flanking CpG sites in the presence of the insertion and the absence of 
it (empty site) within the same individual. However, this comparative study would have been 
complicated by the phenomenon known as X-inactivation which occurs during embryonic 
development. This process involves the global inactivation of most genes present either on the 
maternally or paternally derived X-chromosome in each cell through methylation. New studies 
have come out that have demonstrated that skewed X-inactivation, where imbalanced 
inactivation of the X-chromosomes occurs, is common within the female population [81]. This 
phenomenon of X-inactivation, which is not completely understood, would make it difficult to 
attribute any significant differences in methylation status seen between insertion site and empty 
site to the presence of the L1 alone.  
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Chapter 3: Future Studies 
Future Study #1: SVA in X-linked Dystonia Parkinsonism 
 Introduction: X-linked Dystonia Parkinsonism (XDP) is an adult-onset neurodegenerative 
movement disorder that almost exclusively affects males of Filipino descent [65,66]. The clinical 
phenotype usually presents itself in early adulthood as focal dystonia, which over time, becomes 
generalized to various regions of the body. As the disease progresses, the dystonia either coexists 
with or is replaced by parkinsonism [67]. This disease has no known cure. Most XDP patients 
are found to inherit an identical haplotype; variants of this haplotype are rare [70]. This 
haplotype consists of five specific nucleotide substitutions, a 48bp deletion and a full length 
antisense F-subtype SVA insertion within intron 32 of their TAF1 gene (Fig 3.1). The TAF1 
gene encodes the TATA-binding protein-associated factor-1, which is the largest subunit of the 
transcription factor II D (TFIID) complex which is involved in transcriptional regulation [68, 
69]. Even though most XDP patients share a common haplotype, there is a large amount of 
heterogeneity in the presentation and the progression of the disease (e.g. age of onset, disease 
severity and degree of cognitive dysfunction) [71-73]. The heterogeneity has been linked to the 
presence of the SVA insertion [72, 73].   
SVAs are hominid-specific short interspersed nuclear elements (SINEs) that belong to the 
youngest family of active human retrotransposons (Fig. 3.2). Their name is an acronym 
reflecting their composite nature: human endogenous retrovirus (HERV)-K(HML-2)-derived 
SINE-R, variable-number-of-GC-tandem-repeats (VNTR), Alu-like region, and CCCTCTn 
hexamer array (Fig. 3.2). SVAs are ~ 60% GC-rich, exceeding 70% GC content within their 
VNTR region [54]. SVAs introduce new CpG islands (CGIa) where they insert. They have also 
been found to affect the methylation status of CpGs present in DNA regions flanking the 
insertion [62].   
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Based on all these known properties of SVAs, we hypothesized that the presence of the 
SVA insertion in intron 32 of the TAF1 gene increases the DNA methylation status of TAF1 
DNA flanking the insertion sites of SVA-positive XDP patients. This phenomenon could explain 
the decrease in TAF1 gene expression experienced by individuals with XDP. If true then we 
would expect to see a significant difference in the methylation status of either: 1) X-chromosome 
DNA flanking the TAF1 SVA insertion of male XDP patients vs normal male controls (e.g. 
unaffected related individuals lacking the SVA insertion), or 2) the empty versus filled 








Method: Several bisulfite primers were designed with the aid of MethPrimer bioinformatics tool 
and Primer3Plus [76,77]. These primers were between 20-30 bp in length and were designed to 
preferably amplify regions between 200-500 bp. The first set of primers were designed to 
amplify the region upstream of the SVA insertion in the XDP patients (this region contains 6 
CpGs). The second set of primers were designed to amplify the region downstream of the SVA 
insertion in the XDP patients (this region contains 5 CpGs). The outer primer combinations 
Figure 3.1: XDP haplotype. The haplotype is seen in the red dashed box. It consists of 5 single nucleotide 
substitution annotated as “DSC,” a 48-bp deletion (48 bp Del), and an SVA insertion in intron 32 of the TAF 1 




would be used to amplify the empty site.  See Figure 3.2. This would allow us to compare the 
methylation status in these flanking regions in SVA-positive XDP patients to the same DNA 




Future Directions Discussion: 
This project was very difficult mainly due to the highly repetitive nature of the SVA 
element and the limitations of the bisulfite conversion protocol used. The SVA is characterized 
by 5’ hexamer arrays of (CCCTCT)n that vary in length in between patients (usually between 35 
and 52 repeats) [44]. This fact alone makes primer design very challenging and it is often 
difficult for a PCR reaction to read through the entire repeat. In order to design unique primers 
on the 5’ end, that amplify both the TAF1 flank and 5’ SVA, it requires an amplicon to be a 
minimum of ~300 bp long in the best-case scenario (e.g. patient with 35 hexamer repeats, with a 
minimum of 3 CpG sites present within the flanking DNA). This length is an issue mainly due to 
the limitations of the bisulfite conversion procedure. In this experiment, we used the EpiTect 
MSP Kit for site-specific bisulfite PCR. The ideal amplicon size that they suggest for bisulfite 
converted DNA is ~250 bp [80]. During the conversion process, all unmethylated cytosines are 
converted into uracils. DNA also fragments into single stranded DNA due to the inherent harsh 
nature of this treatment. The fragmented DNA is usually around 500 nucleotides long and the 
DNA recovery rate varies [78]. For the kit that we used, a comparative study found that it 
recovers ~10.2% of the input DNA with average recovery fragment lengths of ~414 nucleotides 
Figure 3.2: XDP SVA schematic. The red arrows refer to primer set 1, to amplify regions upstream of the SVA 
insertion. The green arrows refer to primer set 2, to amplify regions downstream of the insertion. Use the outer 




CELL LINE SUBLINE ENZYME TSD LENGTH pA LENGTH CHR LOCATION TRUNCATION OBSERVATIONS LENGtH GENE ORIENTATION EN cleavage
PA-1 RAM27 SSP1 12 A54 Xp22.2 1 intergenic 8266 - - 5'GATT/G
PA-1 RAM29 HIND3 14 A71 Xq26.3 2 intron 2 of 4 8265 Z96074.1 sense 5'TCTT/A
PA-1 RAM221 HIND3 11 A56 20q13.12 1 Intron 1 of 13 8266 EYA2 sense 5'TTTT/A
PA-1 RAM272 HIND3 17 A25 16p11.1 2 intergenic 8265 - - 5'TTTT/G
PA-1 RAM286 HIND3 12 A131 1q32.2 2 intergenic 8265 - - 5'TTTT/C
[80]. Therefore, the success of this experiment is largely dependent on how exactly the genomic 
DNA fragments during the conversion process.  
Future Study #2: L1 in human ovarian teratocarcinoma cell lines  
We obtained 5 clonally derived human ovarian teratocarcinoma PA1 cell lines, each 
containing a full-length L1 introduced into their genomes by a cell culture retrotransposition 
protocol [75]. These were obtained from our colleague, Dr. Jose Luis Garcia-Perez of the 
University of Edinburgh. In three of the five cell lines, the L1 was introduced into an intergenic 
region (e.g. RAM27, RAM272 and RAM 286). In the other two cell lines, an L1 was introduced 
into the intron of a gene (e.g. RAM29 and RAM 221). See Table 3.1.   
Methods: We designed one set of bisulfite primers to amplify the upstream DNA flanking the 
L1 insertions. We designed a second set of bisulfite primers to amplify the downstream DNA 
flanking the L1 insertions (Fig 3.2). A third primer set was designed to amplify the empty site. 
This will allow us to compare the methylation status in these flanking DNA regions in 
chromosomes with the L1 insertion and those without the insertion (empty site). A significant 
difference in methylation status of the L1-flanking CpG sites would indicate that the presence of 




  Table 3.1: Ovarian teratocarcinoma cell lines. In this table is information regarding 5 clonally derived human 
ovarian teratocarcinoma cell lines. Two of the cell lines are present within introns of a gene, whereas the other 3 










1 p27 5' flank out-F TtTagaattgagagTtggaaggaata 26 OUTER-
292 
 
   8 
*  p27 5'L1 out-R CCCACTATCTAACACTCCCTAATAAAATA 29   
p27 5'flank in-F TTagaattgagagTtggaaggaat 24 IN-233 
**  p27 5'L1 in-R  ATACCTCAAATAAAAATACAAAAATCACC 29   




8 * P29 5’ L1 out-R CCCACTATCTAACACTCCCTAATAAAATA 29   
P29 5’ flank in-F agagagtTtgTtggaggggaaag 23 IN-157 
 **   p29 5' L1 in-R ACTATCTAACACTCCCTAATAAAATAAACC 29 
 
 





* P221 5’ L1 out-R CCCACTATCTAACACTCCCTAATAAAATA 29  
 P221 5’ flank in-F tgttgagtttaagtaatgggtgtatagaag 30 IN- 
315   ** P221 5’ L1 in- R ATACCTCAAATAAAAATACAAAAATCACC 29     
4 p272 5' flank out-F 
  
gtaaaatTtatgaagggaTattttgg 27  




7 * P272 5’ L1 out-R CCCACTATCTAACACTCCCTAATAAAATA 29  
p272 5' flank in-F  aaatTtatgaagggaTattttggag 25 IN- 
163   **  p272 5' L1 in-R   ACTATCTAACACTCCCTAATAAAATAAACC 29      




7 * P286 5’ L1 out-R CCCACTATCTAACACTCCCTAATAAAATA 29   
p286 5'flank in-F gaggaatgtttggttaaaaataaaaag 27 IN-295 
















 We obtained preliminary results from DNA from subline RAM221. RAM 221 had an L1 
insertion introduced into intron 1 of the EYA2 gene. We were able to find a primer combination 
that would amplify and clone the upstream DNA region flanking the L1 insertion. This amplicon 
had a total of 8 CpG sites, with 2 CpGs present within the flanking DNA itself (Fig 3.3 A). We 
were also able to successfully amplify and clone the empty site for RAM 221 DNA. The 
amplicon had a total of 5 CpG sites. Of the 5 CpG sites, 2 of them were the exact same sites 
amplified in the upstream DNA amplicon (Fig. 3.3 B). The other 3 CpG sites were from the 
region downstream of the L1 insertion. We were unable to obtain the actual methylation data 
from this work since COVID-19 forced the shutdown the sequencing facilities. 
  
Figure 3.3. BS Primers Schematic. Primers designed to amplify 5’ upstream flanking DNA of L1 insertion. The outermost and 
innermost of the primers can be used to amplify the empty site.  
*=primer sequence is the same 































Region of interest        BS Primers Sequence 5' to 3' Product size (bp) CpGs in flank 
    EMPTY SITE 
(NO L1 INSERTION) 
p221 5' flank out-F gaaaagtaaataaattaaaattttgagaagag 379 5 
P221 5’ flank in-F tgttgagtttaagtaatgggtgtatagaag 323 3 
P221 3’ flank-R ccatctaccactaacaacaacaaatatc - - 
 
Region of Interest BS Primers Sequence 5' to 3' Product size (bp) Total CpGs CpGs in flank 
 
5’ DNA FLANK 
& 5’ L1 END 
p221 5' flank out-F gaaaagtaaataaattaaaattttgagaagag 410 10 3 
P221 5’ L1 out-R CCCACTATCTAACACTCCCTAATAAAATA 
P221 5’ flank in-F tgttgagtttaagtaatgggtgtatagaag 319 8 2 





























Future Directions Discussion: 
    A. 
Subline: RAM 221 
B. 
Figure 3.4 Subline RAM221. The L1 for RAM221 is inserted into intron 1 of the EYA2 gene located at 20q13.12. 
A. RAM221 DNA was bisulfite converted (see right). We successfully amplified region of the 5’ DNA flank and 5’ end of the L1 using 
nested PCR protocol (primers shown above). The final PCR product was ~319 bp and was cloned into a TOPO-TA vector (pCR2.1, 
Invitrogen) and run on a gel. 
B. The empty site was also amplified using nested PCR (primers shown above). The final PCR product was ~323 bp and was cloned into a 
TOPO-TA vector (pCR2.1, Invitrogen) and run on a gel. 





 This project began in mid-February when we first obtained the samples from our 
colleague Dr. Jose Luis Garcia-Perez of the University of Edinburgh. We had already designed 
several primers to amplify the upstream DNA flanks and the empty sites in all 5 sublines (Fig. 
3.2). We wanted to successfully amplify these regions before attempting to also amplify the 
downstream DNA flanks in these sublines (since the presence of the poly A tail on the 3’ L1 end 
presents a greater challenge for PCR extension). Initially, many of our primer combinations were 
unsuccessful, so we had to redesign new primers that would work on our bisulfite-treated DNA 
samples. We were starting to obtain favorable results before COVID-19 halted our progress.   
The successful completion of this project would have required methylation data from 
CpG sites both upstream and downstream of where the L1 insertion is in all the sublines. This 
data must include information about the methylation status of the same flanking CpG sites in the 
chromosome with the insertion and the chromosome without it (the empty site). We had planned 
to obtain this data by amplifying the flanking CpG sites using the primer combinations listed in 
Figure 3.2. We were successful in amplifying the empty site and 5’flanking DNA of subline 
RAM221 before COVID-19 halted our progress. With the entirety of our data we would have 
been able to do bisulfite conversion methylation analysis by using the Quantification tool for 
Methylation Analysis (QUMA). QUMA is a commonly used program that uses Fisher's Exact 
Test statistics to determine whether any differences in methylation levels are statistically 
significant [79]. QUMA would have allowed us to determine whether the presence of the L1 
insertion led to statistically significant changes in the average methylation levels observed in 
each flanking CpG site (both upstream and downstream from the insertion).  
We were expecting the average methylation levels of the flanking CpG sites to be 
significantly elevated in the presence of the L1 insertion relative to the empty site. We expected 
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for this to be true for CpG sites located both upstream and downstream of the insertion. We 
expected for this to be the case for all 5 sublines, regardless of whether the L1 insertion was 
present in an intergenic or intronic region. This result would have supported our hypothesis that 
new L1 insertions can affect the methylation status of flanking DNA and for those L1s inserted 
in genes, to investigate effects on gene expression.  This preliminary data has laid the 
groundwork for this and the above studies to be continued at a later date following the reopening 
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